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A regulatory system for soluble immune response suppressor produc-
tion in steroid-responsive nephrotic syndrome. Patients with nephrotic
syndrome frequently have suppressed immune responses. Previously, it
has been determined that subjects with steroid-responsive nephrotic
syndrome (SRNS) produce the lymphokine, soluble immune response
suppressor (SIRS). In the present group of experiments, a potential
pathway of suppressor cell activation was investigated. Sera from
patients with SRNS stimulated normal CD8 lymphocytes to produce
SIRS. Serum SIRS-inducing activity was abrogated by treatment with
proteinase K or boiling, but was not affected by dialysis, acidification to
pH 2, or heating to 56°C. This serum factor could be distinguished
functionally and antigenically from SIRS and from interferon (IFN)a or
IFN7. Supernatants of cultured patient lymphocytes enriched for CD4
cells were also found to activate normal CD8 lymphocytes to produce
SIRS. The lymphocyte-derived activity showed similar characteristics
to those of the serum factor. Molecular weight of both factors was
estimated to be 13,000 to 18,000 daltons by gel filtration chromatogra-
phy, and activity of serum and lymphocyte supernatant from the same
patients eluted with similar patterns on reversed-phase HPLC. These
data suggest that serum SIRS-inducing activity is derived from a
suppressor-inducer lymphocyte, and indicate the presence of a regula-
tory mechanism for SIRS production in steroid-responsive nephrotic
patients.
The close association of suppressed immune responsiveness
with the occurrence of minimal change nephrotic syndrome
(MCNS) has suggested that the immunological and renal abnor-
malities in this condition have a common pathogenesis [1].
Although progress has been made in identifying numerous
defects of immune function and in characterizing the mecha-
nism of albuminuria [2], the cause(s) of these phenomena is not
known. We have previously determined that urine and serum
from certain nephrotic patients contain soluble immune re-
sponse suppressor (SIRS) [3], an antigen-nonspecific suppres-
sor lymphokine that inhibits antibody production in vitro [4],
and antibody production and delayed-type hypersensitivity
responses in vivo [5]. Evaluation of a spectrum of nephrotic
patients indicated that SIRS was produced by all patients who
had nephrosis and responded to corticosteroid therapy [6].
Peripheral blood mononuclear cells (PBMC) from patients
with steroid-responsive nephrotic syndrome (SRNS) secrete
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SIRS in culture without requiring activation by exogenous
agents, suggesting that activated, circulating lymphocytes are
the source of SIRS in body fluids. This may be accounted for by
the observation that sera from patients with SRNS activate
normal lymphocytes to produce SIRS. SIRS production itself
may be steroid-sensitive, since SIRS disappears from body
fluids shortly after initiation of steroid therapy. In vitro studies
have shown that secretion of SIRS by activated lymphocytes is
not prevented by steroids. However, hydrocortisone blocks
activation of suppressor cells to produce SIRS by patient serum
or other SIRS-inducing agents such as conpanavalin A and
interferons [6]. Taken together, these data suggest the existence
in SRNS of a regulatory mechanism by which suppressor cells
may be activated to produce SIRS.
The striking correlation between steroid-sensitive SIRS pro-
duction and steroid responsiveness of albuminuria suggests that
these phenomena have a common origin [6]. Thus, delineation
of the events which lead to SIRS production might also provide
information relating to the pathogenesis of proteinuria in ne-
phrotic patients. In the present paper, the SIRS-inducing activ-
ity in the serum of nephrotic patients is further characterized. It
results from the presence of a 13,000 to 18,000 dalton protein
which can be distinguished from other substances previously
determined to activate suppressor cells to produce SIRS. A
likely source of this factor is a CD4 lymphocyte present
among the PBMC of patients with steroid-responsive MCNS.
These findings define a regulatory pathway for SIRS produc-
tion, and raise the possibility that suppressed immunity in
nephrotic patients may result, at least in part, from the presence
of activated suppressor-inducer cells and a population of cells
that respond to the inducer population by producing SIRS.
Methods
Unless otherwise specified, all chemicals were reagent grade
and purchased from commercial sources.
Patient population
Clinical materials were obtained from patients with MCNS or
its histopathologic variant forms [2] under care of the Renal
Divisions of Children's Hospital, Barnes Hospital, or the Jew-
ish Hospital of St. Louis, Washington University School of
Medicine. Diagnosis was established by renal biopsy, except in
certain children aged two to seven in whom clinical and
serologic criteria indicated a presumptive diagnosis of MCNS
[2]. A patient was classified as being steroid-responsive if
151
152 Schnaper: SIRS-inducing factor in nephrotic patients
diuresis occurred, proteinuria disappeared, and serum albumin
concentration became normal with steroid therapy.
Collection and treatment of test samples
All specimens were obtained from patients or healthy volun-
teers under protocols approved by the Washington University
School of Medicine and Jewish Hosoital of St. Louis Human
Studies Committees. Blood was obtained from patients at initial
presentation or during relapse before initiation of steroid ther-
apy, since treatment has previously been found to cause SIRS
to disappear from patient serum and lymphocyte supernatant.
After centrifugation of whole clotted blood, serum was re-
noved, filter sterilized and stored at —20°C until testing.
Peripheral blood mononuclear cells (PBMC) were obtained by
withdrawal of whole blood into a heparinized syringe. The
sample was diluted 1:1 with Hanks' balanced salt solution and
centrifuged through a Ficoll/sodium diatrizoate gradient accord-
ing to the method of Boyum [71.
In vitro activation of lymphocytes to produce SIRS
After washing, 3 x 106 PBMC from healthy subjects were
suspended in 1.5 ml RPMI 1640 medium supplemented with
penicillin/streptomycin, glutamine, nonessential amino acids,
and 10% fetal calf serum (Rehatuin, Kankakee, Illinois, USA).
Serum or lymphocyte supernatant was added to cultures that
were then incubated in sterile, 12-mi round-bottom, plastic
culture tubes for 24 hours in 5% humidified CO2 in air at 37°C.
The cells were washed twice with Hanks' solution and resus-
pended in fresh culture medium for an additional 24 hours.
After centrifugation to remove the PBMC culture supernatant
was harvested by pasteur pipette. Supernatant fluids were
assayed for suppressive activity on polycional, 1gM plaque-
forming cell (PFC) responses. Briefly, human splenocytes were
obtained from cadaver kidney transplant donors at the time of
organ harvest, processed as described previously [4], and
stimulated with 4 g/ml pokeweed mitogen (Sigma Chemical
Co., St. Louis, Missouri, USA). After six days an aliquot of the
splenocytes was added to a mixture of rabbit anti-human 1gM
antiserum (Zoehringer-Mannheim, Indianapolis, Indiana, USA),
and sheep erythrocytes coated with staphylococcal protein A
(Sigma), in melted agarose (Seakem, FMC Corporation, Rock-
land, Maine, USA). After the mixture was allowed to cool on a
slide, the gel was flooded with diluted guinea pig complement
(Rockland, Inc., Gilbertsville, Pennsylvania, USA), causing zones
of hemolysis around 1gM-producing cells [8].
Fluids that caused >50% suppression of PFC response com-
pared with the response of control cultures were considered to
show significant suppressive activity. Suppression was con-
firmed to be SIRS-mediated by the ability of monoclonal
anti-SIRS antibody coupled to Sepharose 4B (Sigma Chemical
Co.) to absorb suppressive activity from solution [3]. In exper-
iments comparing the effect of various treatments of SIRS-
inducing activity, results are expressed as units of activity,
derived by titrating suppressive activity in cultures and defining
one unit as the volume of supernatant determined graphically to
cause 50% suppression of PFC responses [3].
Separation of T cell subpopulations
Monoclonal antibodies to human CD4, helper/inducer cell
(OKT4), and CD8, suppressor/cytotoxic cell (OKT8), surface
antigens were used to isolate these two populations as de-
scribed previously [4]. Briefly, 2 x i07 PBMC in 2 ml RPMI
1640 medium were incubated at 4°C for 45 minutes with 10 .d
monoclonal antibody reconstituted according to the package
insert (Ortho-mune, Ortho Diagnostic Systems, Raritan, New
Jersey, USA), washed, and resuspended in rabbit complement
at 37°C for 30 minutes. Alternatively, antibody-treated cells
were layered onto 100 x 15 mm sterile plastic culture dishes
(Fisher Scientific Co., Pittsburgh, Pennsylvania, USA) coated
with goat anti-mouse IgG (0.75 tg/ml). Nonadherent cells were
obtained after the plates were gently swirled, and adherent cells
were then removed by vigorous pipetting. After treatment, cells
were washed and resuspended at 2 x 106 cells/ml in culture
medium. Treatment with antibody and complement resulted in
less than 1% of the remaining cells expressing the considered
antigen; positive selection resulted in greater than 90% of cells
expressing the antigen.
Chromatography of fluids
Serum or lymphocyte supernatant was fractionated by gel
filtration chromatography or reversed-phase high performance
liquid chromatography. For estimation of molecular weight, 1
ml of serum or culture supernatant was applied to a I x 45 cm
column Sephacryl S-200 in phosphate-buffered saline and
eluted with the same buffer. Fractions of I ml were obtained.
The void volume was 16 ml; the column was calibrated with
aldolase, bovine serum albumin, chymotrypsinogen A and
cytochrome c. HPLC was performed by dialyzing the material
against 50 mM trifluoracetic acid (TFA), pH 2, and application
of 0.4 ml to an RP-8 (C-8) column (Licrosorb, Darmstadt, FRG)
in the same buffer. Protein was eluted with an increasing
gradient of acetonitrile. Fractions of 0.5 ml were obtained; the
pH was adjusted to 7.0 before the fractions were tested for
ability to activate normal suppressor cells. Initially, solvent was
removed from the fractions by lyophilization and resuspension
in distilled water; however, it was ultimately determined that
addition of individual fractions to PBMC cultures at 2% (voV
vol) did not affect activation of suppressor cells and this
procedure was discontinued.
Enzyme-linked immunoabsorbent assay (ELISA) for
interferon
"Capture" ELISA was performed to determine whether sera
or culture fluid contained proteins antigenically similar to IFN.
For IFNa, 96-well plastic plates (Immulon, Dynatech Labore-
tories, Chantilly, Virginia, USA) were coated with mouse
monoclonal anti-IFNa (Boehringer Mannheim), 5 U/ml in PBS,
pH 9.2, overnight. The plates were blocked with 3% BSA in
PBS. Control and assay fluids were titrated in 50 p1 aliquots into
the wells and allowed to incubate for 60 minutes at room
temperature. After washing, the plates were developed with
horse anti-human IFNa antiserum (Chemicon, Temecula, Cal-
ifornia, USA), biotinylated anti-horse antiserum (Vector Labo-
ratories, Burlingame, California, USA), avidin-alkaline phos-
phatase, and p-nitrophenyl phosphate as a substrate. A similar
assay for IFNy was performed for us by Beth Viviano and
Robert Schreiber (Dept. of Pathology, Washington University
School of Medicine). The sensitivity of these assays was 30
p1ml (IFNa) and 20 piml (IFNy); these limits represent much
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Fig. 1. Activation of SIRS production by serum from a patient with
SRNS. Normal PBMC were cultured with 2.5% (vol/vol) serum from a
single healthy donor (D), a patient with steroid-responsive nephrotic
syndrome (•), or a patient who did not respond to steroids (s), or in
plain medium (0); for 24 hours. After washing, the PBMC were
resuspended in culture medium. After 24 additional hours, supernatant
fluids were harvested and added in graded doses to pokeweed mitogen-
stimulated splenocyte cultures. Five days later, the splenocytes were
assayed for polyclonal, 1gM PFC responses. Suppression was con-
firmed as SIRS-mediated by absorption from solution with monoclonal
anti-SIRS antibodies coupled to Sepharose.
less than the amount of IFN required to induce SIRS produc-
tion [41.
Results
Activation of suppressor cells by serum from steroid-
responsive nephrotic patients
Previously we reported that sera from several patients with
steroid-responsive nephrotic syndrome activated suppressor
cells to produce SIRS [6]. A larger number of nephrotic patients
has been evaluated for serum SIRS-inducing activity. All 11
steroid-responsive nephrotic patients who have been tested
showed SIRS-inducing activity. In contrast, serum from five of
six steroid unresponsive patients did not activate suppressor
cells (Fig. I). One adult patient whose urine and serum con-
tained SIRS, and whose lymphocytes secreted SIRS in culture,
had serum SIRS-inducing activity but did not respond to a trial
of steroid therapy. These data indicate that, in general, contin-
Table 1. Cell surface phenotype of lymphocytes activated to produce
SIRS by serum from patients with SRNS
Lymphocyte treatment Serum
SIRS activity
U/mi
Unselected PBMC —
Unselected PBMC 25 .d
PBMC + C' 25 d
PBMC + anti-OKT8 + C' 25 sl
PBMC + anti-OKT4 + C' 25
OKT4' 25 l
OKT8 25d
OKT8 —
<5
100
100
<5
40
<5
>100
<5
a Lymphocytes, treated as indicated, were cultured at 2 x 106 cells in
1 ml with or without patient serum. After 24 hours, the cells were
washed in HBSS and resuspended in fresh medium. Twenty-four hours
later, culture supernatant fluids were harvested and tested for suppres-
sive activity in pokeweed mitogen-stimulated splenocyte cultures.
Units of activity/ml were derived by determining graphically the quan-
tity of supernatant required to suppress the PFC response by 50%.b OKT4 and OKT8 cells were those which adhered to plates
coated with goat anti-mouse Ig after incubation with the indicated
antibody (Methods).
ued evaluation of nephrotic patients confirms a strong relation-
ship between SRNS and SIRS production.
Cell surface phenotype of lymphocytes activated by patient
serum to produce SIRS
Concanavalin A, interferons and histamine directly activate
100 CD8, suppressor-effector lymphocytes to produce SIRS [4, 9]
To determine whether patient serum acts directly upon a CD8
cell, subpopulations of normal lymphocytes were treated with
serum from patients with SRNS. Table 1 shows the results of
one of three similar experiments. Although treatment of the
normal PBMC with anti-OKT4 antibody and rabbit complement
did not prevent them from secreting SIRS, suppressive activity
was not detected in supernatant of cells depleted of CD8
lymphocytes with anti-OKT8 antibody and complement. In
experiments utilizing positive selection of lymphocyte subpop-
ulations by plate separation technique, anti-OKT8-treated cells,
selected by adherence to goat anti-mouse IgG-coated plates,
produced SIRS after being exposed to patient serum. In con-
trast, cells selected for expression of the CD4 antigen did not
produce SIRS. PBMC that did not adhere to plates after
incubation with anti-CD4 or anti-CD8 functioned similarly to
cells treated with the same antibody and complement (data not
shown). These data indicate that, like other, previously identi-
fied SIRS-inducing agents, serum from patients with SRNS
activates CD8 lymphocytes to produce SIRS.
Initial characterization of serum SIRS-inducing activity
Because patient sera also contain SIRS, it was possible that
suppressive activity could result from carry-over of SIRS into
the lymphocyte supernatants after the PBMC were washed.
Further, SIRS-inducing activity could result from the presence
of a feedback loop by which SIRS amplified its own production.
To investigate these possibilities, initial physical characteriza-
tion of serum SIRS-inducing activity was undertaken. Figure 2
shows the results of one such experiment. SIRS was inactivated
by treatment with proteinase K (Sigma Chemical Co.). Simi-
larly, serum SIRS-inducing activity was prevented by treatment
4000
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Fig. 2. Physical characteristics of serum SIRS-inducing activity. Nor-
mal PBMC were cultured in plain medium, or in the presence of 2.5%
patient serum treated as follows: (-0-) no serum, (-I-) patient serum,
(-U-)dialysis 10,000 mol. wt; (-•-) proteinase K; (-A-) 56°C X 30 mm,
(--A--) 100°C x 30 mm; (-Y-) pH 2 x 30 mm. After 24 hrs, the cells were
washed and then cultured for 24 additional hours. Supernatants were
then harvested and tested for suppressive activity on PFC responses.
of the serum with proteinase K, 10 p.g/ml for one hour at 37°
followed by refrigeration overnight. However, unlike SIRS [4]
and IFNy [10], acidification to pH 2 did not inactivate the serum
SIRS-inducing factor. SIRS-inducing activity was not removed
by dialysis of serum against phosphate-buffered saline across a
membrane with a molecular weight restriction of 10,000 dal-
tons, or by heating to 56°C, but activity was abolished by
heating serum to 100°C. Each of these characteristics was
confirmed in experiments with at least two additional sera.
To further distinguish serum SIRS-inducing activity from that
of SIRS itself, patient serum was absorbed with a cocktail of
monoclonal anti-murine SIRS antibodies that have previously
been found to cross react with human SIRS [3]. As shown in
Figure 3, SIRS-inducing activity was not removed from serum
by this treatment. In four different experiments, 70 to 100% of
suppressive activity was removed from patient serum by anti-
body absorption without affecting SIRS-inducing activity. Re-
sidual suppression caused by antibody-absorbed patient serum
in splenocyte cultures was prevented by addition of i07 M
hydrocortisone, suggesting that suppression resulted from se-
Supernatant added, J
Fig. 3. Antigenic comparison of the SIRS-inducing factor with SIRS
and IFN. Aliquots of serum from a patient with SRNS were incubated
with monoclonal anti-SIRS antibodies (U), or rabbit anti-human IFNa
(A) or anti-human IFNy (•) antiserum, coupled to sepharose. These
antibodies were confirmed to absorb SIRS or IFN activity, respec-
tively, from solutions containing these cytokines. Treated sera were
then compared to untreated serum (I) or medium (0) for ability to
activate normal PBMC to secrete suppressive activity.
rum SIRS-inducing activity causing SIRS production by the
splenocytes (data not shown).
Comparison of the SIRS-inducing protein with JFN
Interferons are common biological proteins that have previ-
ously been found to activate suppressor cells to produce SIRS.
To determine whether patient sera contained anti-viral IFN-like
activity, three sera were simultaneously assayed for SIRS-
inducing activity and evaluated by a commercial laboratory for
inhibition of viral cytopathogenic effect on human foreskin
fibroblast cultures (Biofluids, Inc., Rockville, Maryland, USA).
As shown in Table 2, no significant interferon-like anti-viral
activity was present, whereas all three sera showed SIRS-
inducing activity. To further consider the possibility that the
SIRS-inducing protein was similar to an interferon, anti-IFN
antisera (Interferon Sciences, New Brunswick, New Jersey,
USA) were coupled to CNBr-activated Sepharose 4B. Absorp-
tion of serum with anti-IFNa or anti-IFN7 Sepharose did not
remove SIRS-inducing activity (Fig. 3). These same prepara-
tions of Sepharose were found to effectively remove IFN from
solution (tested by T. Ratliff, Dept. of Urologic Surgery, the
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Table 2. SIRS-inducing activity and viral inhibitory
from patients with SRNS
activity in sera
Serum source
SIRS produced by
serum-treated
PBMC, U/mi
Serum
IFN titer,
U/mi
Control
Patient 1
Patient 2
Patient 3
<5
35
50
80
<5
<5
<5
<5
Normal PBMC were treated with 25 .d/ml serum to activate SIRS
production, as described in Table 1. Aliquots of the same sample were
tested commercially for IFN activity as determined by inhibition of
viral cytopathogenic effect on cultured fibroblasts.
15,000
Supernatant added, jiI
Fig. 4. Secretion of SIRS-inducing activity by lymphocytes from a
patient with SRNS. PBMC from a patient or from a healthy volunteer
were treated with anti-OKT4 antibody and complement, anti-OKT8
antibody and complement, or complement alone, washed and cultured
for 24 hours. Symbols are, source of activating agent: (0) control
lymphocytes; (0) control lymphyocytes + anti-OKT8 Ab + c'; (•)
patient lymphocytes; (U) patient lymphocytes + anti-OKT8 Ab + C';
(A) patient lymphocytes + anti-OKT4 Ab +c'. Supernatant fluids (2.5
percent vol/vol) from these cultures were added to fresh cultures of
PBMC which were washed after 24 hours and resuspended in culture
medium. After 24 additional hours, culture supernatant was tested for
suppressive activity on pokeweed mitogen-stimulated splenocyte cul-
tures. Suppression was confirmed as SIRS-mediated by absorption
from solution with monoclonal anti-SIRS antibody.
Table 3. Determination of the surface phenotype of lymphocytes
producing a SIRS-inducing factor by plate separation
SIRS activity induced
by supernatant in
Cell population normal PI3MC, U/mi
Whole PBMC <10
OKT4-adherent >100
OKT8-adherent <10
OKT4-nonadherent <10
OKT8-nonadherent 100
Patient PBMC were incubated with monoclonal anti-CD4 (OKT4,
helper/inducer cell) or anti-CD8 (OKT8 suppressor/cytotoxic) antibody
and then allowed to adhere to a plate coated with goat anti-mouse IgG
antiserum. Normal PBMC treated with anti-OKT4 antibodies do not
secrete a substance which activates PBMC to produce SIRS. Similar
results were obtained in a separate experiment with PBMC from
another patient.
Treatment of supernatant SIRS produced U/mi
Control 90
Acidification of pH 2 83
56°C x 30 mm 90
Anti-SIRS antibody 100
Anti-IFN-a antiserum 100
Anti-IFN-y antiserum 40
Proteinase K 10 g/m1 <5
Patient lymphocytes were treated with anti-OKT8 antibody and
rabbit complement, then cultured for 24 hours. The culture supematant
fluid was harvested, treated as indicated, and added (25 d/ml) to
cultures of normal PBMC. After 24 hours, these cultures were washed
and resuspended in fresh medium. After an additional 24 hours,
supernatant of the normal PBMC was harvested and tested for SIRS
activity. Similar results were obtained in two other experiments.
'a
0
0
Table 4. Partial characterization of lymphocyte-derived SIRS-
inducing activity
10,000
5000
0 10
Secretion of a SIRS-inducing substance by patient
lymphocytes
Detection of SIRS-inducing activity in patient serum mdi-
30 100 200 cated that a suppressor cell-activating protein is present in the
peripheral circulation of patients with SRNS. To determine
whether the SIRS-inducing protein may be derived from circu-
lating immunocytes, PBMC from a nephrotic patient were
cultured for 24 hours and the supernatant was harvested and
added to fresh cultures of normal PBMC. Mter 24 hours, these
cells were washed and cultured for an additional 24 hours.
Supernatant fluids from the normal PBMC cultures were then
harvested and tested for SIRS activity in splenocyte cultures. In
the experiment shown in Figure 4, PFC responses were de-
creased somewhat by addition of material from lymphocytes
treated with patient cell supernatant. Patient lymphocytes de-
pleted of suppressor-effector cells with anti-OKT8 antibody and
complement induced a more significant degree of suppressive
activity. Removal of CD4 patient cells with anti-OKT4 anti-
body and complement prevented induction of suppression.
Unlike patient lymphocytes, normal lymphocytes treated with
anti-OKT8 antibody and complement did not induce suppres-
sion. Suppressive activity was confirmed to be SIRS-mediated
by absorption with anti-SIRS antibody (data not shown). Sim-
ilar findings were made with cells obtained from seven different
steroid-responsive nephrotic patients. Lymphocytes from three
Jewish Hospital of St. Louis). Finally, three sera were evalu-
ated by ELISA for the presence of a protein antigenically
similar to IFN'y. None was detected. These data show that the
serum SIRS-inducing protein may be distinguished functionally
and antigenically from conventional interferons.
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Table 5. Cell surface phenotype of lyumphocytes activated to
produce SIRS by supernatant of CD4 patient lymphocytes
PBMC treatment SIRS activity U/mi
Whole PBMC 90
C' alone 100
anti-OKT4 Ab + C' >300
anti-OKT8 Ab + C, <10
OKT4-adherent <10
OKT8-adherent >300
Lymphocyte subpopulations were obtained as indicated, washed,
and resuspended at 2>< 106 cells/mI. Supernatant of CD4 lymphocytes
from a patient with SRNS was added to the different subpopulations (20
d/m1). After 24 hours, the cells were washed and resuspended in
culture medium. After 24 additional hours, supernatant was harvested
and titrated for suppressive activity in pokeweed mitogen-activated
splenocyte culture. Similar results were obtained in two separate
experiments.
U,
Fraction number
steroid-unresponsive patients did not show SIRS-inducing ac-
tivity (data not shown). In two cases, sufficient lymphocytes
from patients with SRNS were available for positive selection
of lymphocyte subpopulations by plate separation. As shown in
the representative experiment in Table 3, PBMC expressing the
CD4 surface antigen released SIRS-inducing activity into the
culture supernatants, whereas cells expressing the CD8 antigen
(including SIRS-secreting cells) did not release a SIRS-inducing
factor. These data indicate that PBMC from patients with
SRNS produce a substance which activates normal PBMC to
produce SIRS, that enrichment for CD4 lymphocytes in-
creases the degree of suppressive activity induced, and that
production of the factor requires the presence of cells express-
ing the CD4 antigen.
Initial characterization of the SIRS-inducing factor produced
by patient PBMC
To obtain preliminary characterization of the lymphocyte-
derived factor, a series of experiments was carried out similar
to those employed to characterize the serum factor. In the
experiment shown in Table 4, SIRS-inducing activity of the
lymphocyte supernatant was not abrogated by acidification to
pH 2 or by heating to 56°C. Absorption of the supernatant with
anti-SIRS or anti-IFN antibodies also did not remove activity.
However, treatment with proteinase K did destroy activity.
ELISA of three different supernatants of patient cells treated
with anti-OKT8 antibody and complement did not detect IFNa
or IFNy (data not shown). To determine whether lymphocyte-
derived, SIRS-inducing activity acts directly on a CD8 cell,
normal lymphocyte subpopulations were treated with superna-
tant from CD4 patient lymphocytes. As shown in Table 5,
SIRS was recovered from CD8 lymphocytes treated with the
SIRS-inducing factor. Taken together, these data describe
physical, antigenic and functional similarities between the se-
rum and lymphocyte-derived SIRS-inducing proteins in patients
with SRNS, and distinguish these proteins from IFNs.
Further comparison of serum and lymphocyte-derived SIRS
inducing activity
Preliminary physical characterization suggested that both of
these moieties were proteins with Mr greater than 10,000. Gel
filtration chromatography with Sephacryl S-200 indicated that
Fig. 5. Gel filtration chromatography of serum (—) and lymphocyte-
derived (---) SIRS-inducing activity from the same patient. Serum or
supernatant (1 ml) of CD4-enriched lymphocytes from the same patient
with SRNS were subjected to chromatography on a Sephacryl S-200 gel
column. Fractions (1 ml) were collected and tested for ability of 25 .d/ml
to activate normal lymphocytes to produce SIRS, as determined by
titration in pokeweed mitogen-stimulated splenocyte cultures.
individual samples of SIRS-inducing activity eluted with an
estimated molecular weight of 13,000 to 18,000 daltons in
physiologic buffer. In five separate experiments, serum and
lymphocyte supernatant from the same patient were subjected
to chromatography on the same column. In each case, activity
of the serum and the lymphocyte-derived factors eluted in
identical fractions (Fig. 5), yielding identical molecular weight
estimations for the proteins from the two different sources.
To further compare the two SIRS-inducing factors, active
fractions from gel filtration chromatography of serum and
lymphocyte supernatant from the same patient were subjected
to reversed-phase HPLC on an RP-8 column in 50 mrt trifluo-
roacetic acid. Protein was eluted with a linearly increasing
gradient of acetonitrile. Eluted fractions were tested for SIRS-
inducing activity. In the experiment shown in Figure 6, a small
amount of SIRS activity was obtained from lymphocytes
treated with material that did not appear to adsorb onto the
column. A larger amount of SIRS was obtained from lympho-
cytes treated with material eluting from the column at approx-
imately 25% acetonitrile. In this patient, and in one of three
others similarly tested, another peak of activity was obtained at
50% acetonitrile with the lymphocyte-derived factor only.
When the individual peaks were reapplied to the column, each
eluted at the concentration identical to that at which it had
previously eluted, with the exception of the 50% acetonitrile
peak. Activity from this peak was found to elute in the
load-wash, at 25% acetonitrile and at 50% acetonitrile. Along
with the physical characterization of the two factors, the similar
elution patterns on reversed-phase HPLC of the serum and
lymphocyte-derived SIRS-inducing activity show that they re-
sult from the presence of similar proteins.
Discussion
The strong association of suppressed immunity with MCNS
suggests that the immunological abnormality is in some way
0 14 16 18 20 22 24 26 28 30
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Fig. 6. Reversed-phase HPLC of serum and
lymphocyte-derived SIRS-inducing activity from the
same patient. Symbols are: (0) SIRS activity; (—)
optical density 280 nm; (---) % acetonitrile. Serum or
supernatant (0.4 ml) was equilibrated against 50 mM
TFA, pH 2, and applied to an RP-8 column in the
same buffer. Protein was eluted with an increasing
gradient of acetonitrile. Fractions obtained were
adjusted to pH 7 with NaHCO3 and then tested for
ability to activate SIRS production by normal
PBMC. Similar results were obtained in 3 additional
experiments.
related to the cause of proteinuria [1]. However, it has been
difficult to critically evaluate this relationship because the
nature and origin of the immune dysfunction are uncertain.
Previously we reported that patients with steroid-responsive
nephrotic syndrome produce SIRS [6]. Although it is not certain
that SIRS causes the immunological disorder(s) found in SRNS,
injection of SIRS in mice causes suppression of immune re-
sponses similar to that observed in nephrotic patients. Since
both SIRS production [3] and immune suppression [11, 12]
decrease with steroid therapy, these findings support the hy-
pothesis that SIRS contributes to immune suppression. In
contrast, there is no evidence to support a role for SIRS in
mediating proteinuria. Chronic administration of immunosup-
pressive doses of SIRS does not cause proteinuria in healthy
mice (unpublished observation). Further, patients with several
other diseases who are not nephrotic may also produce SIRS
(unpublished observation). While these observations could re-
flect the requirement for an additional condition that allows
SIRS to induce proteinuria, it is at least as likely that a common
event causes both albuminuria and immune suppression in
SRNS. Thus, delineation of the circumstances leading to the
presence of SIRS in body fluids could identify events related to
the onset of nephrosis.
To begin to define the events leading to SIRS production,
evidence was sought for a SIRS-inducing agent in nephrotic
patients. Serum from patients with SRNS activated normal
CD8 cells to produce SIRS, as did supernatant fluid from
patient lymphocytes enriched for cells expressing the CD4
antigen. It is not certain why enrichment for CD4 cells was
required for patient cell supernatant to induce significant sup-
pressive activity in normal PBMC. Competing effects of other
cell products may interfere with activation of suppressor cells
by the SIRS-inducing protein. Further, CD8 T cells among the
patient lymphocytes could conceivably absorb SIRS-inducing
activity from solution.
The serum and lymphocyte-derived factors share a number of
characteristics. Both migrate with an apparent Mr of 13,000 to
18,000 daltons on gel filtration chromatography in PBS; under
the same conditions, SIRS activity migrates at 110,000 to
160,000 daltons. Serum and lymphocyte-derived SIRS-inducing
activity, and SIRS-mediated suppression, are destroyed by
proteolytic digestion with proteinase K. However, unlike SIRS,
the SIRS-inducing activity is stable at pH 2; this characteristic
also distinguishes the SIRS-inducing agent(s) from gamma
interferon [10]. In experiments designed to further distinguish
patient SIRS-inducing activity from that of interferons, it was
determined that sera and lymphocyte supernatants having sup-
pressor cell-inducing activity contained no antigenic or func-
tional evidence for the presence of IFN proteins, and that
absorption with anti-interferon antisera coupled to Sepharose
did not remove SIRS-inducing activity from either serum or
supernatant. The SIRS-inducing activity was also not recog-
nized by monoclonal anti-SIRS antibodies.
HPLC of serum and lymphocyte supernatant showed similar
patterns of elution for SIRS-inducing activity. Since the elution
characteristics of the load-wash and 25% acetonitrile peaks
were maintained upon repeat chromatography, these probably
represent stable forms of the protein. In contrast, portions of
the 50% acetonitrile peak, seen only in some lymphocyte
supernatants, appeared in the load-wash and 25% acetonitrile
fractions on repeat chromatography, suggesting that lympho-
cyte-derived activity eluting at 50% represented a less stable
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form (or precursor) of the protein. Taken together with the
physical characterization and antibody absorption experiments,
the data obtained by HPLC indicate that the serum and lym-
phocyte-derived factors are similar. This raises the possibility
that serum SIRS-inducing activity in SRNS may be derived
from circulating, activated suppressor-inducer lymphocytes.
This activity does not result from a feedback loop by which
SIRS amplifies its own production. Instead, activation is medi-
ated by a protein which has not previously been identified as
inducing suppressor cells to produce SIRS.
A number of other agents produced by lymphocytes have
been reported to induce suppressor cell activity. IFNy causes
suppression in several immunological systems [4, 13, 14].
Prostaglandins, which may be elevated in nephrosis [15], acti-
vate suppressor cells [16]. Morimoto et al reported that a CD4
T lymphocyte, along with CD8 cells, is required for suppres-
sion of primary antibody response to antigen [17]. A suppressor
cell induction factor (SIF) has been described that is resistant to
56°C and acidification to pH 2 and is precipitated by 50 to 80%
ammonium sulfate [18]. Interleukin (IL)-2 has been reported to
activate suppressor cells [191, and may require a T suppressor
cell growth factor (TSGF) for its action in stimulating suppres-
sor cell populations [20]. This latter factor, reported by Rich
and co-workers, may selectively enhance expression of IL-2
receptors on suppressor cells. Workers in the same laboratory
have defined a series of events requiring TSGF, IFNy, IL-2,
and macrophage-derived prostaglandins for full expression of
suppressor cell activity [20, 21]. A variety of interactions among
lymphocytes of different phenotypes is required to produce all
of these factors [22, 23].
In the present series of experiments, the number of lympho-
cytes available from most of our subjects has precluded rigor-
ous elimination of possible trace numbers of contaminating cells
during positive selection experiments. Thus, although a CD4
T lymphocyte is necessary for its production, other lymphocyte
subsets could participate in producing the SIRS-inducing pro-
tein. Further, products of these other cells could mediate
activation of CD8, SIRS-producing cells by the factor. Al-
though the data presented in this paper suggest that the protein
found in nephrotic subjects is not interferon or any other
substance previously identified as inducing SIRS production,
the SIRS-inducing agent does share similarities with SIF [18].
To date, we have not been able to induce production of SIRS by
incubating PBMC with either IL-i or IL-2 (unpublished obser-
vation). Comparison with activating agents reported in other
suppressor systems will be facilitated by further characteriza-
tion of the protein described in the present series of experi-
ments.
In addition, characterization of the SIRS-inducing substance
may be relevant to understanding the pathogenesis of MCNS.
Previous observations indicate that the productive life of a
normal or nephrotic SIRS-secreting lymphocyte is less than 24
hours. Thus, constant stimulation of suppressor cells must be
occurring in vitro to account for the large amount of SIRS
continuously produced by patients with SRNS. The data pre-
sented in this paper suggest that the origin of the immunological
abnormality does not lie with the suppressor cell, but may
instead be traced through a series of prior stimulating events. It
is noteworthy that, in the small number of non-nephrotic
subjects in whom serum SIRS activity has been identified,
SIRS-inducing activity has not been found. Thus, the specificity
of these observations is supported by their distinction among
nephrotic patients according to steroid-responsiveness, and
distinction from other diseases by the presence of an unique
regulatory system for SIRS production. Experiments are in
progress to: (a) more fully evaluate the role of the CD4 cell in
this system; (b) determine conditions that lead to or inhibit
production of the SIRS-inducing protein; and, (c) further char-
acterize both immunological and nonimmunological effects of
the SIRS-inducing substance.
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